Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to α vβ 3 receptor expressed in Kaposi's sarcoma

Molecular Imaging

Volumn 4, Issue 2, 2005, Pages 75-87

  Kwon, Sunkuk ^a   Ke, Shi ^a   Houston, Jessica P ^a   Wang, Wei ^b   Wu, Qingping ^b   Li, Chun ^b   Sevick Muraca, Eva M ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Intensified charge coupled device; Kaposi's sarcoma; Near infrared fluorescence imaging; Pharmacokinetic analysis

Indexed keywords

KAPOSI'S SARCOMA; NEAR-INFRARED FLUORESCENCE IMAGING; PHARMACOKINETIC ANALYSIS;

FLUORESCENCE; GRAFTS; IMAGING SYSTEMS; PHARMACOKINETICS; TISSUE; TUMORS;

MEDICAL IMAGING;

ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; FLUORESCENT DYE; OLIGOPEPTIDE; VITRONECTIN RECEPTOR;

ANIMAL; ARTICLE; BIOSYNTHESIS; DOSE RESPONSE; DRUG DELIVERY SYSTEM; FEMALE; KAPOSI SARCOMA; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; PATHOLOGY; STAINING;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; FLUORESCENT DYES; INTEGRIN ALPHAVBETA3; MICE; MICE, NUDE; OLIGOPEPTIDES; SARCOMA, KAPOSI; STAINING AND LABELING;

EID: 26944443953     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.1007/11546924_8     Document Type: Article

References (45)

1. Hynes, RO (1987). Integrins: A family of cell surface receptors. Cell. 48:549-554.
2. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, Mueller BM (2001). Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci USA. 98: 1853-1858.
3. v integrins. Science. 270:1500-1502.
4. Wong NC, Mueller BM, Barbas CF, Ruminski P, Quaranta V, Lin ECK, Smith JW (1998). Alpha(v) integrins mediate adhesion and migration of breast carcinoma cell lines. Clin Exp Metastasis. 16:50-61.
5. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA (1990). Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression. Cancer Res. 50:6756-6764.
6. Stromblad S, Cheresh DA (1996). Integrins, angiogenesis and vascular cell survival. Cbem Biol. 3:881-885.
7. Folkman J (1985). Toward an understanding of angiogenesis: Search and discovery. Perspect Biol Med. 29:10-36.
8. Carmeliet P, Jain RK (2000). Angiogenesis in cancer and other diseases. Nature. 407:249-257.
9. Clark RA, Tonnesen MG, Gailit J, Cheresh DA (1996). Transient functional expression of alpha v beta 3 on vascular cells during wound repair. Am J Pathol. 148:1407-1421.
10. Max R, Gerritsen RRCM, Nooijen PTGA, Goodman SL, Sutler A, Keilholz U, Ruiter DJ, DeWaal RM (1997). Immunohistochemical analysis of integrin alpha v beta 3 expression on tumor-associated vessels of human carcinomas. Int J Cancer. 71:320-324.
11. Natali PG, Hamby CV, Felding-Habermann B, liang BT, Nicotra MR, DiFilippo F, Giannarelli D, Temponi M, Ferrone S (1997). Clinical significance of alpha(v)beta(3) integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 57:1554-1560.
12. Eliceiri BP, Cheresh DA (1999). The role of av integrins during angiogenesis: Insights into potential mechanisms of action and clinical development. J Clin Invest. 103:1227-1230.
13. v gene expression in human melanoma tumorigenicity. J Clin Invest. 89:2018-2022.
14. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1157-1164.
15. Buckley CD, Pilling D, Henriquez NV, Parsonage G, Threlfall K, Scheel-Toellner D, Simmons DL, Albar AN, Lord JM, Salmon M (1999). RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 397:534-539.
16. Zitzmann S, Ethemann V, Schwab M (2002). Arginine-glycineaspartic (RGD)-peptide binds to both tumor and tumorendothelial cells in vivo. Cancer Res. 62:5139-5143.
17. Safai B, Johnson KG, Myskowski PL, Koziner B, Yang SY, Cunningham-Rundles S, Godbold JH, Dupont B (1985). The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 103:744-750.
18. 3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. FASEB J. 16:2000-2002.
19. Benelli R, Adatia R, Ensoli B, Stetler-Stevenson WG, Santi L, Albini A (1994). Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an antiangiogenic therapy. Oncol Res. 6:251-257.
20. 3 in brain tumor xenografts. Cancer Res. 64:8009-8014.
21. 3 integrin-targeted optical contrast agents with dynamic optical imaging. J Biomed Opt. to appear May/June.
22. 3 in human tumor xenografts. Mol Imaging. 3: 343-351.
23. Houston JP, Ke S, Wang W, Li C, Sevick-Muraca EM. Quality analysis of in vivo NIR fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probes submitted to J Biomed Opt.
24. Ke S, Wang W, Wu Q, Charnsangavej C, Houston JP, Chow D, Sevick-Muraca EM, Li C. Dual optical and nuclear imaging of integrin in human melanoma xenografts using a single imaging probe. J Clin Cancer. Submitted for publication.
25. Hwang K, Houston JP, Rasmussen J, Ke S, Li C, Sevick-Muraca EM. Enhanced fluorescent optical imaging with improved excitation light rejection. Mol Imaging. Submitted for publication.
26. Gurfinkel M, Thompson AB, Ralston W, Troy TL, Moore AL, Moore TA, Gust JD, Tatman D, Reynolds JS, Muggenburg B, Nikula K, Pandey R, Hawrysz DJ, Sevick-Muraca EM (2000). Pharmacokinetics of ICG and HPPH-car for detection of normal and tumor tissue using fluorescence, near-infrared reflectance imaging: A case study. Photochem Photobiol. 72:94-102.
27. Ke S, Wen X, Gurfinkel M, Charnsangavej C, Wallace S, SevickMuraca EM, Chun Li (2003). Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts. Cancer Res. 63:7870-7875.
28. 64Cu-DOTA-[Lys3]Bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 45: 1390-1397.
29. van Hagen PM, Breeman WAP, Bernard HF, Schaar M, Mooij CM, Srinivasan A, Schmidt MA, Krenning EP, de Jong M (2000). Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy. Int J Cancer. 90: 186-198.
30. Castel S, Pagan R, Mitjans F, Pitulats J, Goodman S, Jonczyk A, Huber F, Vilaro S, Reina M (2001). RGB peptides and monoclonal antibodies, antagonists of ctv-integrin, enter the cells by independent endocytic pathways. Lab Invest. 81:1615-1626.
31. 3 integrin directed therapeutics. Bioconjug Chem. 13:128-135.
32. Vera DR, Stadalnik RC, Trudeau WL, Schneibe PO, Krohn KA (1991). Measurement of receptor concentration and forwardbinding rate constant via radiopharmacokinetic modeling of technetium99m-galactosyl-neoglycoalbumin. J Nucl Med. 32: 1169-1176.
33. Godavarty A, Thompson AB, Roy R, Eppstein MJ, Zhang C, SevickMuraca EM (2005). Detection of multiple targets in breast phan toms using fluorescence enhanced optical imaging. Radiology. 235:148-154.
34. Ntziachristos V, Tung CH, Bremer C, Weissleder R (2002). Fluorescence molecular tomography resolves protease activity in vivo. Nat Med. 8:757-761.
35. 3 integrin expression. J Nucl Med. 45:1776-1783.
36. 64Cu- labeled RGD peptide. Bioconjug Chem. 15:41-49.
37. 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging. 31:1081-1089.
38. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 61:1781-1785.
39. 3 integrin binding peptides in a nude mouse model. Cancer Res. 42: 6146-6151.
40. Haubner R, Wester HJ, Burkhart F, Senekowitsch-Schmidtke R, Weber W, Goodman SL, Kessler H, Schwaiger M (2001). Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med. 42:326-336.
41. 3 integrin atagonists: A new class of tracers for tumor targeting. J Nucl Med. 40:1061-1071.
42. 3 integrin-targeted nanoparticles. Circulation. 108:2270-2274.
43. Sivolapenko GB, Skarlos D, Pectasides D, Stathopoulou E, Milonakis A, Sirmalis G, Stuttle A, Courtenay-Luck NS, Konstantinides K, Epenetos AA (1998). Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur J Nucl Med. 25:1383-1389.
44. 18F-labeled RGD and octreotide analogs. J Nucl Med. 45:892-902.
45. 18F-labeled dimeric RGD peptide. Mol Imaging. 3:96-104.